The Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund (ETW) provides investors with diversified exposure to U.S. and global equities through an index call-write strategy. Currently trading at a 10.88% discount to NAV, ETW offers an attractive 8.24% market yield, primarily funded by option premiums and capital gains rather than dividends. This payout appears sustainable but remains sensitive to equity market downturns due to its reliance on capital appreciation and options income. Its global diversification and lower tech sector concentration compared to the S&P 500 may help it perform relatively well if U.S. equity valuations decline.
The Eaton Vance Tax-Managed Global Buy-Write Opportunities Fund (ETW) is presented here with Pluang's market data for context. For readers following US stocks on Pluang as of Oct 12, 2026 03:11 WIB, breadth showed 101 of 150 priced US stocks rising while 48 fell. Notable gainers included Alibaba Group (BABA) at USD 111.37 with a 5.36% increase and a typical hold time of 112 days, Tencent Music Entertainment Group (TME) at USD 8.38 up 5.28% with a 68-day hold, and Palantir Technologies Inc (PLTR) at USD 209.05 rising 5.17% with a 79-day hold time.
Acoramidis, a drug for transthyretin amyloid cardiomyopathy (ATTR-CM), was linked to an 18% lower risk of death, hospitalization, and disease progression compared to tafamidis in a large U.S. electronic health record study of 2,684 patients. The stud...
Stellantis revealed six concept cars from its iconic brands at an exclusive event before the Paris Motor Show, highlighting its FaSTLAne 2030 strategy focused on innovation, customer experience, and diverse mobility solutions. These concepts, includi...
Freenome announced improved clinical validation results for its updated SimpleScreen™ CRC blood test, showing an 18.2% sensitivity for advanced precancerous lesions (APLs), up from 13.7% in the original test. Sensitivity for high-grade dysplasia APLs...
Latigo Biotherapeutics is currently trading below its IPO value despite showing strong potential with its drug onzotrigine, which has demonstrated better efficacy in acute pain compared to Vertex's Journavx. The company benefits from leveraging Verte...
The VistaShares Target 15 Berkshire Select Income ETF (OMAH) is rated as a Hold due to its defensive nature and high payout supported by an aggressive option overwrite strategy. However, this approach causes gradual net asset value erosion, especiall...
